Indications
SIPRODIS 500 mg film-coated tablet is indicated in the treatment of infections. Particular attention should be paid to the available information on bacterial resistance to ciprofloxacin before initiating treatment. Official recommendations regarding the appropriate use of antibacterials should be considered. - In adults: · Lower respiratory tract infections due to Gram-negative bacteria * exacerbations of chronic obstructive pulmonary disease * bronchopulmonary infections in cases of cystic fibrosis or bronchiectasis · Chronic purulent otitis media · Acute exacerbations of chronic sinusitis , particularly due to Gram-negative bacteria · Urinary tract infections · Reproductive tract infections * gonococcal urethritis and cervicitis due to susceptible strains of Neisseria gonorrhoeae * orchiepididymitis, including infections due to susceptible strains of Neisseria gonorrhoeae * upper gynecological infections, including infections due to susceptible strains of Neisseria gonorrhoeae · Gastrointestinal infections (e.g. traveler's diarrhea) · Intra-abdominal infections · Skin and soft tissue infections due to Gram bacteria negative · Malignant otitis externa · Osteoarticular infections · Prophylaxis of invasive Neisseria meningitidis infections · Anthrax (prophylaxis after exposure and curative treatment) Ciprofloxacin can be used for the treatment of febrile neutropenic patients whose bacterial origin is suspected. - In children and adolescents: · Bronchopulmonary infections in cases of cystic fibrosis due to Pseudomonas aeruginosa · Complicated urinary infections and pyelonephritis · Anthrax disease (prophylaxis after exposure and curative treatment) Ciprofloxacin can also be used to treat severe infections in children and adolescents, if necessary. Treatment should only be initiated by doctors experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.
API
Ciprofloxacin
Therapeutic area
Infectiology/Antibiotics
Forms
Scored film-coated tablet
Dosage
500 mg
Presentation
B/14
Table
A